Sunday, December 2, 2012

Cannabis Genome Browser

The Cannabis Genome Browser: http://genome.ccbr.utoronto.ca/

Cannabis sativa Genome Browser Gateway: http://genome.ccbr.utoronto.ca/cgi-bin/hgGateway

Cannabis Genome Browser Introduction

http://www.youtube.com/watch?v=6WrclzzubBI



Schematic illustration of the cannabinoid biosynthesis pathways


Cannabis Genome Downloads:

canSat3
Raw sequencing data is available through the NCBI short read archive.

finola1


http://cphx.org/2012/07/mckernan-cannabis-genome/

Cannabis Medicinal Genomics:
http://www.medicinalgenomics.com/resources/cannabis/

Combinatorial Biosynthesis of Tetrahydrocannabinol:
http://www.tb.bci.tu-dortmund.de/images/stories/fotos/webseite/scientific_highlights-thc.pdf

Monday, September 17, 2012

Antineoplastic activity of cannabinoids.

Antineoplastic activity of cannabinoids.

Journal of the National Cancer Institute, Vol. 55, No. 3, September 1975 

Abstract

Lewis lung adenocarcinoma growth was retarded by the oral administration of delta9-tetrahydrocannabinol (delta9-THC), delta8-tetrahydrocannabinol (delta8-THC), and cannabinol (CBN), but not cannabidiol (CBD). Animals treated for 10 consecutive days with delta9-THC, beginning the day after tumor implantation, demonstrated a dose-dependent action of retarded tumor growth. Mice treated for 20 consecutive days with delta8-THC and CBN had reduced primary tumor size. CBD showed no inhibitory effect on tumor growth at 14, 21, or 28 days. Delta9-THC, delta8-THC, and CBN increased the mean survival time (36% at 100 mg/kg, 25% at 200 mg/kg, and 27% at 50 mg/kg, respectively), whereas CBD did not. Delta9-THC administered orally daily until death in doses of 50, 100, or 200 mg/kg did not increase the life-spans of (C57BL/6 times DBA/2)F1 (BDF1) mice hosting the L1210 murine leukemia. However, delta9-THC administered daily for 10 days significantly inhibited Friend leukemia virus-induced splenomegaly by 71% at 200 mg/kg as compared to 90.2% for actinomycin D. Experiments with bone marrow and isolated Lewis lung cells incubated in vitro with delta9-THC and delta8-THC showed a dose-dependent (10(-4)-10(-7)) inhibition (80-20%, respectively) of tritiated thymidine and 14C-uridine uptake into these cells. CBD was active only in high concentrations (10(-4)).
PMID: 1159836 
 
 
Erowid: http://www.erowid.org/plants/cannabis/references/journal/1975_munson_nci_1/1975_munson_nci_1_text.shtml
UKCIA: http://www.ukcia.org/research/AntineoplasticActivityOfCannabinoids/index.php

Thursday, June 28, 2012

Visualisation of the endocannabinoid signaling system

Visualisation of the endocannabinoid signaling system


Visualization of the endocannabinoid signaling system from Leanne C

YouTube: http://www.youtube.com/watch?v=jznQfMj9RWM

A Master's Research Project submitted fo Masters of Science, Faculty of Medicine, University of Toronto. Developed in collaboration with Biomedical Communications, Department of Biology, University of Toronto at Mississauga, The Canadian Consortium for the Investigation of Cannabinoids and with funding provided in part by the Quebec Pain Research Network.

The endocannabinoid signaling system is composed of the cannabinoid receptors; their endogenous ligands, the endocannabinoids; the enzymes that produce and inactivate the endocannabinoids; and the endocannabinoid transporters. The endocannabinoids are a new family of lipidic signal mediators, which includes amides, esters, and ethers of long-chain polyunsaturated fatty acids. Endocannabinoids signal through the same cell surface receptors that are targeted by Δ9-tetrahydrocannabinol (Δ9THC), the active principles of cannabis sativa preparations. The biosynthetic pathways for the synthesis and release of endocannabinoids are still rather uncertain. Unlike neurotransmitter molecules that are typically held in vesicles before synaptic release, endocannabinoids are synthesized on demand within the plasma membrane. Once released, they travel in a retrograde direction and transiently suppress presynaptic neurotransmitter release through activation of cannabinoid receptors. The endocannabinoid signaling system is being found to be involved in an increasing number of pathological conditions. In the brain, endocannabinoid signaling is mostly inhibitory and suggests a role for cannabinoids as therapeutic agents in central nervous system (CNS) disease. Their ability to modulate synaptic efficacy has a wide range of functional consequences and provides unique therapeutic possibilities. http://www.kingstoncompassion.org

VLC Screens: https://picasaweb.google.com/qnbs420/VisualisationOfTheEndocannabinoidSignalingSystem?authuser=0&authkey=Gv1sRgCOiA65_tz57_VQ&feat=directlink

Tuesday, June 5, 2012

Cannabis Alchemy: Modern Hash Making & Cancer Treatment: Cannabinoids Patent

Cannabis Alchemy: The Art of Modern Hash Making
Methods for Preparation of Extremely Potent Cannabis Products
Scribd: http://www.scribd.com/doc/24508920/The-Art-of-Modern-Hash-Making


 
Exploring methods of cannabis resin extraction: http://cannabisdigest.ca/cms/2012/07/concentrating-on-cannabinoids/


Cannabis Digest: http://cannabisdigest.ca/cms/



Phytocannabinoids in the Treatment of Cancer:  http://patentscope.wipo.int/search/en/detail.jsf?docId=WO2011110866
This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS), as a prophylactic or in the treatment of cancer. Typically the cancer to be treated is a cancer of the: prostate, breast, skin, glioma, colon, lung or a bone or lymph metastasis.
WIPO Patentscope: http://patentscope.wipo.int/search/en/detail.jsf;jsessionid=B9CB10CCFDF36A8282061577DDDF1D35.wapp2?docId=WO2011110866&recNum=1&maxRec=&office=&prevFilter=&sortOption=&queryString=&tab=PCTDescription

Figure 1: Overview of Botanical Drug Substance (BDS) preparation: 

Applicants: 
GW PHARMA LIMITED [GB/GB] http://www.gwpharm.com/
OTSUKA PHARMACEUTICAL CO. LIMITED
[JP/JP] http://www.otsuka.co.jp/en/

Wednesday, March 28, 2012

Cannabinoids (Handbook of Experimental Pharmacology)

The present book is an outstanding summary of many aspects of cannabinoid research. It provides current knowledge about the pharmacology and therapeutic potential of cannabinoids as well as knowledge about the pharmacology, physiology, and pathology of the endogenous cannabinoid systems. The chapters are written by scientists who have made or are still making major contributions to the field. This book may well help generate novel ideas on how to approach the study of emotions.
Springer: http://www.springer.com/biomed/pharmaceutical+science/book/978-3-540-22565-2

Archive Search: http://archive.org/search.php?query=cannabinoids

Friday, December 23, 2011

The Medicinal Uses of Cannabis and Cannabinoids

 
The Medicinal Uses of Cannabis and Cannabinoids
Cannabis research has moved beyond its use as an illegal recreational drug. Increasingly, focus is on its potential as a therapeutic substance, particularly in serious chronic illnesses such as multiple sclerosis.
This new title describes current research findings relating to the medicinal use of cannabis and cannabinoids. Topics covered include the pharmacology, formulation, safety and efficacy of cannabis as a therapeutic agent; growth and breeding of cannabis as a medicine; cannabis for neuropathic pain treatment and for multiple sclerosis; clinical studies and the development of cannabis-based medicine; and forensic and international control of cannabis.
Written by experts in the UK and USA, this is an essential reference for pharmacists, doctors, pharmacologists and all other healthcare professionals with an interest in cannabis-derived medicines for symptom relief of intractable diseases.
Edited by 
  • Geoffrey W Guy - Executive Chairman, GW Pharmaceuticals, UK
  • Brian A Whittle - Scientific Director
  • Philip J Robson - Medical Director, GW Pharmaceuticals, UK
Pharmaceutical Press: http://www.pharmpress.com/product/9780857110176/the-medicinal-uses-of-cannabis-and-cannabinoids 

Amazon: http://www.amazon.com/Medicinal-Uses-Cannabis-Cannabinoids-Geoffrey/dp/0853695172 

GoogleBooks: http://books.google.com/books?id=AznCzOxvrtwC&hl=de&source=gbs_book_other_versions

GW Pharmaceuticals: Research & Development
GW's research explores the potential therapeutic applications of cannabinoids and the endocannabinoid system across a wide range of disease areas. http://www.gwpharm.com/r-and-d.aspx

Tuesday, December 20, 2011

Journal of Cannabis Therapeutics (2001-2004)


Journal of Cannabis Therapeutics (2001-2004): http://www.cannabis-med.org/index.php?tpl=journallist&id=9&lng=en


The Journal of Cannabis Therapeutics was published by Haworth Press, Binghamton, New York, and edited by Ethan Russo.

Publication of the Journal of Cannabis Therapeutics ceased in 2004.

The entire contents of the Journal of Cannabis Therapeutics (2001-2004) is now available free online (even to non-members) at the International Association for Cannabinoid Medicines: http://www.cannabis-med.org/index.php?tpl=journallist&id=9&lng=en 


2001 


Abstract ] PDF of the full text ] 

Marijuana (Cannabis) as Medicine 
Marijuana (Cannabis) as Medicine
Abstract ] PDF of the full text ] 

Book Reviews 
Book Reviews
Abstract ] PDF of the full text ] 


2002 

Year 2002 - Issue No. 1 

Editorial 
Editorial
Abstract ] PDF of the full text ] 

Book Reviews 
Book Reviews

Introduction
Abstract ] PDF of the full text ]

Historical Review 
Cannabis Treatments in Obstetrics and Gynecology: A Historical Review

Endocannabinoids 
Endocannabinoid Degradation and Human Fertility

Cannabinoids and Feeding 
 Cannabinoids and Feeding: The Role of the Endogenous Cannabinoid System as a Trigger for Newborn Suckling

Hyperemesis Gravidarum 
Hyperemesis Gravidarum and Clinical Cannabis: To Eat or Not to Eat?

Marijuana Use and Pregnancy 
Marijuana Use and Pregnancy

Harm Reduction 
Cannabis and Harm Reduction: A Nursing Perspective

Cannabis in Jamaica 
Crack Heads and Roots Daughters: The Therapeutic Use of Cannabis in Jamaica

Hashish 
One Woman's Work in the Use of Hashish in a Medical Context

Tourette Syndrome 
Combined Treatment of Tourette Syndrome with Delta-9-THC and Dopamine Receptor Antagonists

Case Report 
Personal Account of Medical Use of Cannabis

Multiple Sclerosis 
Cannabis in Multiple Sclerosis: Women’s Health Concerns

Editorial
Abstract ] PDF of the full text ]

Pharmacokinetics 
Clinical pharmacokinetics of cannabinoids

Medical Cannabis Use 
The acceptance of medicinal marijuana in the U.S.

An interview with Markus Storz  
Abstract ] PDF of the full text ] 


Year 2003 - Issue No. 2

Editorial
Abstract ] PDF of the full text ]

Cannabis in HIV/AIDS 
Cannabis Use by Persons Living with HIV/AIDS: Patterns and Prevalence of Use

Survey 
Survey on the Medical Use of Cannabis and THC in Germany

Palliative Care 
Attitudes and Beliefs about the Use of Cannabis for Symptom Control in a Palliative Population

Cultivation of Cannabis 
Guidelines for Cultivating Cannabis for Medicinal Purposes [Voorschriften voor de Verbouw van Cannabis voor Medicinale Doeleinden]

Meeting report 
Cannabinoids and Pain Management Symposium: American Academy of Pain Management 13th Annual Clinical Meeting, 2002, Reno, NV, USA

Book Review 
Book Review

Abbreviations 
GW Pharmaceuticals List of Abbreviations and Definitions of Terms

Clinical Study 
A Single Centre, Placebo-Controlled, Four Period, Crossover, Tolerability Study Assessing, Pharmacodynamic Effects, Pharmacokinetic Characteristics and Cognitive Profiles of a Single Dose of Three Formulations of Cannabis Based Medicine Extracts (CBMEs) (

Clinical Study 
A Phase I, Open Label, Four-Way Crossover Study to Compare the Pharmacokinetic Profiles of a Single Dose of 20 mg of a Cannabis Based Medicine Extract (CBME) Administered on 3 Different Areas of the Buccal Mucosa and to Investigate the Pharmacokinetics of

Clinical Study 
A Phase I, Double Blind, Three-Way Crossover Study to Assess the Pharmacokinetic Profile of Cannabis Based Medicine Extract (CBME) Administered Sublingually in Variant Cannabinoid Ratios in Normal Healthy Male Volunteers (GWPK0215)

Clinical Studies 
Cannabis and Cannabis Based Medicine Extracts: Additional Results

Review and Outlook 
Future of Cannabis and Cannabinoids in Therapeutics
Abstract ] PDF of the full text ] 


2004 

Year 2004 - Issue No. 1 

Editorial 
Editorial

Vaporizer 
Cannabis Vaporizer Combines Efficient Delivery of THC with Effective Suppression of Pyrolytic Compounds

Pharmacodynamics 
Clinical Pharmacodynamics of Cannabinoids

Alcohol Dependency 
Cannabis as a Substitute for Alcohol: A Harm-Reduction Approach

International Association for Cannabinoid Medicines (IACM): http://www.cannabis-med.org/index.php?tpl=journallist&id=9&lng=en 

Medical Cannabis: http://medicalcannabis.com/Resources/jcant-on-line

Tuesday, December 13, 2011

Cannabis Therapeutics Marijuana Education & Dispensary Safety, Colorado

Marijuana Education and Dispensary Safety (Colorado)
Cannabis Therapeutics: http://cannabistherapeutics.net

Marijuana Education (PDF): http://cannabistherapeutics.net/MarijuanaEducation.pdf
Designed as an in-depth guide to medical marijuana in Colorado, this presentation examines legal, safety, scientific, personal, and societal consequences of the drug’s use as medicine with an intended audience comprised of both the law enforcement and patient communities.
The purpose of this booklet is four-fold:
  • 1. To educate the law enforcement community about the legality of medical marijuana in Colorado.
  • 2. To offer proper safety guidelines for the protection of both the patients and the community as dispensaries and cooperatives develop.
  • 3. Give a brief background in science, focusing on harmful side effects medical validity, and proper usage guidelines.
  • 4. To open a line of friendly communication between representatives of both the medical marijuana and law enforcement communities.
Contacts:

For more information on a particular topic, the following professionals can be contacted at:

Legal Questions:
Attorney Warren Edson, 303-831-8188
Attorney Brian Vicente, 720-890-4247
Medical/ Scientific Questions:
Robert Melamede, PHD, 719-262-3135
Matthew Schnur, Researcher, 719-439-0817
All questions and inquiries may be sent to:
info@cannabistherapeutics.net
Cannabis Therapeutics, LLC is the largest medical marijuana resources facility to proudly serve patients of the state of Colorado. Working with local law enforcement, state officials, legal experts, medical physicians, and researchers, Cannabis Therapeutics sets a standard of both safety and consistent quality to its members as well as the community at large. 
Cannabis Therapeutics: http://cannabistherapeutics.net

Marijuana Education (PDF): http://cannabistherapeutics.net/MarijuanaEducation.pdf
Additional information about Cannabis Regulation in Colorado:



Chemicals in marijuana:

1.  Cannabinoids: 78 known as of 2008.  
2.  Terpenoids:  103 known
3.  Fatty Acids: 12 known
4.  Non-cannabinoid Phenols: 16 known
5.  Flavanoids: 19 known- these are potential antioxidants
Many of the cannabinoids and terpenoids found within marijuana work together to create an additive effect called synergy. Synergy refers to an increased effect caused by combining two or more drugs, an effect that could not be caused by either drug alone.
Synergy of cannabinoids is supported by the fact that Marinol (synthetic, pure THC), has a higher incidence rate of panic attacks and paranoia than clinical studies utilizing whole marijuana  plant.
The  following  list  describes  comparisons  in  medical  efficacy  of marijuana  constituents  to  conventional  medications,  in  addition  to  illustrating  point  of potential synergy:
 1.  CBD, CBG, CBN, β-myrcene (terpenoid), quercitan (flavanoid), and Cannflavin A, are but a few constituents other than THC that exert anti-inflammatory effects.

2.  Cannflavin A is 30x more potent than aspirin in reducing inflammation in rheumatoid synovial cells (arthritis model).

3.  THC has 20x anti-inflammatory effects of aspirin, twice that of hydrocortisone

4.  CBD has anti-inflammatory properties at lower doses than aspirin

5.  Quercitan is a powerful  antioxidant. Also found to be anticarcinogenic and anti-inflammatory, which may mitigate the potential for marijuana smoking to cause lung cancer.
•  Source: Chapter 7 of “Medical uses of cannabis and Cannabinoids”, Geoffrey Guy, 2004.
Marijuana is an extremely difficult plant to study for clinical effects due to the variation in the abundant amount of therapeutic chemicals.
The scientific method applied to pharmaceuticals does not currently allow for synergistic therapies, likely because of their variation in outcome between individuals. Ultimately, the true therapeutic potential of marijuana remains untapped until a new scientific method is developed to identify clinical outcomes with varying quantities of multiple chemicals.
Devices are now available called vaporizers. Vaporizers do not use fire for the combustion (burning) of marijuana. Instead, they use heat to vaporize the medicinal materials without causing the formation of carcinogens.

Studies have unequivocally confirmed the effectiveness and safety of vaporization.

•  Hazekamp, Arno, et al. 2005. Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. Journal of Pharmaceutical Sciences 95: 1308-1317.

The National Institute of Health published research proving that the psychoactive component of marijuana, THC, has a greater antioxidant capacity than both vitamins A and E.

These  findings  occurred  eight  years  prior  to  the FDA statement that no valid scientific research supports medical marijuana!

•  Hampson, AJ, et al. 1998. Cannabidiol and (-)delta-9-tetrahydrocannabinol are neuroprotective antioxidants. Proceedings of the National Academies of Science 95: 8268-8273. 

PDF: http://cannabistherapeutics.net/MarijuanaEducation.pdf

Sunday, December 4, 2011

Cannabinoid Conference 2011

 
6th Conference on Cannabinoids in Medicine and
5th European Workshop on Cannabinoid Research, September 8–10, 2011 

A joint meeting of the European Workshop on Cannabinoids and the International Association for Cannabinoid Medicines (IACM)

Programs and Abstracts (PDF): http://www.cannabis-med.org/meeting/Bonn2011/abstractbook.pdf

Sponsors:
  • Deutsche Forschungsgemeinschaft
  • International Society of Neurochemistry
  • Bedrocan
  • Almirall Hermal
  • Bionorica Ethics
  • Echo Pharmaceuticals
  • THC Pharm
  • Meda Pharmaceuticals
Conference Poster: http://www.cannabis-med.org/meeting/Bonn2011/poster.pdf

International Association for Cannabinoid Medicines: http://cannabis-med.org

 
Internet: http://www.bonn2011.org


ORGANIZING COMMITTEE
 

Co-Chairs
Franjo Grotenhermen
Andreas Zimmer

Members
Manuel Guzman
Roger Pertwee
Ethan Russo

SCIENTIFIC COMMITTEE
Itai Bab
Javier Fernandez-Ruiz
Franjo Grotenhermen
Manuel Guzman
Roger Pertwee
Ethan Russo
Mark Ware
Andreas Zimmer  



CONFERENCE PROGRAM

Thursday, September 8
 

13:00-19:00 Registration

15:00-15:15

Opening and Introduction
 

15:15-16:00 Plenary Lecture I

Daniele Piomelli

The Endocannabinoid System: New tools lead to new insights
Chair: A. Zimmer

16:00-16:30 COFFEE BREAK

16:30-18:15 Session I - Brain functions

Chair: M. Guzman

16:30-17:00 Ken Mackie

Mechanisms of CB1 receptor desensitization

17:00-17:30 Beat Lutz

Cell type-specific functions of the brain's endocannabinoid system

17:30-17:45 Ana Luisa Terzian

The cross-talk between dopamine and cannabinoid in emotions and cognition: the role of cannabinoid CB1 receptor in neurons expressing dopamine D1 receptors

17:45-18:00 Patrik Roser

Auditory mismatch negativity generation in schizophrenia with and without comorbid cannabis use

18:00-18:15 Miriam Schneider

Social rejection in adolescent rats induces persistent alterations in pain perception and CB1 receptor expression - A new animal model with relevance for borderline personality disorder

18:30-21:00 GET-TOGETHER WITH WINE TASTING

Festsaal (see floor plan)


Friday, September 9

09:00-17:00 Registration

09:00-09:45 Plenary Lecture II

George Kunos

The peripheral endocannabinoid/CB1 receptor system as a novel therapeutic target in obesity/metabolic syndrome 


Chair: I. Bab

09:45-10:00 COFFEE BREAK

10:00-11:45 Session II - Metabolism and inflammation

Chair: B. Lutz

10:00 - 10:30 Vincenzo Di Marzo

Targeting the peripheral endocannabinoid system with plant cannabinoids and n-3 polyunsaturated fatty acids to Combat abdominal obesity-associated metabolic disorders

10:30-11:00 Sophie Lotersztajn

Cannabinoid receptors in liver pathophysiology: new insights and therapeutic openings

11:00-11:15 Zvi Vogel

Effects of cannabinoids on microglial gene expression and their role in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis

11:15-11:30 Sabine Steffens

Deficiency of fatty acid amide hydrolase is associated with a vulnerable plaque phenotype in atherosclerosis-prone mice

11:30-11:45 Jose Antonio Martinez Orgado

Cannabidiol reduces hypoxic-ischemic brain damage by modulating excitoxicity, oxidative stress and inflammation. Role of CB2 and 5HT1A receptors

11:45-13:00 LUNCH

13:00-15:00 Session III - Neuroinflammation

Chair: S. Maione

13:00-13:30 Javier Fernandez-Ruiz

Anti-inflammatory and neuroprotective potential of Sativex-like medicines in Huntington's disease: from basic research to clinical studies

13:30-14:00 Andreas Zimmer

CB2 receptor signaling in neuroinflammation

14:00-14:30 Andrea Hohmann

Role of endocannabinoid signalling in the control of pain initiation

14:30-14:45 Onintza Sagredo

Potential exidation of 2- AG by COX-2 enhances malonate toxicity in the striatum: Relevance for cannabinoid treatments in Huntington's Disease

14:45-15:00 Judith Alferink

CB2 signaling is required for susceptibility of cerebral malaria

15:00 -17:00 POSTER SESSION I AND COFFEE BREAK

[IACM General Meeting]

17:00-18:30 Session IV - Translational and preclinical studies

Chair: J. Fernandez-Ruiz

17:00-17:30 Manuel Guzman

Therapeutic potential of cannabinoids as anticancer drugs

17:30 - 18:00 Aron Lichtman

Targeting Endocannabinoid Hydrolytic Enzymes to treat Neuropathic and Inflammatory Pain

18:00-18:15 Evelyn Gaffal

CB1 receptor deficiency in epidermal keratinocytes promotes contact allergic inflammation and delays epidermal barrier repair response

18:15-18:30 Ethan Russo

Cannabidiol and TRPV1: Turning down the heat (and pain)


Saturday, September 10

08:30-12:00 Registration

08:45-10:50 Session V- Bone

Chair: I. Bab

08:45-09:15 Itai Bab

Novel Cannabinoid Skeletal Targets

09:15-09.45 Ruth Ross

Cannabinoids and bone biology: latest developments

09:45-10:05 Sabatino Maione

The expression of TRPV1 channel and ofCB1 vs CB2 cannabinoid receptors is modified in osteoclasts from osteoporotic women

10:05-10:20 Thomas Randau

CB2 receptor expression in human spinal mesenchymal stem cells
from patients with osteoporosis

10:20 - 10:35 Jiirg Gertsch

Osteoclastogenesis inhibition by a novel class of biphenyl-type
cannabinoid CB2 receptor inverse agonists

10:35-10:50 COFFEE BREAK

11:05-12:05 Session VI - Herbal cannabis

Chair: W. Notcutt

10:50-11:20 Roger Pertwee

Phytocannabinoid Pharmacology: New Discoveries and Therapeutic Possibilities

11:20-11:35 Jeffrey Hergenrather

Clinical improvement and reduction of immunosuppressive drug therapy in cannabis treated patients with Crohn's Disease and ulcerative colitis

11:35-11:50 Arno Hazekamp

The medicinal use of cannabis and cannabinoids: an international survey on methods of intake

11:50-12:05 Sarah Martin

Cannabis oils produced by a multiple sclerosis patient reveals the potentials of cannabis when used in its natural form

12:05-13:15 LUNCH

13:15-14:30 POSTER SESSION II

14:30-16:30 Sativex, Nabilone, and Dronabinol

Chair: D. Abrams

14:30-15:00 Philip Robson

Sativex - a clinical overview

15:00-15:30 William Notcutt - Title N.N.

A Retrospective Description of the Use of Nabilone in UK Clinical Practice

15:30-16:00 Tjalling Erkelens

Bedrocan Research and Development - stimulating the development of herbal cannabis based-products

16:00-16:15 Tim Beumer

First in human trial of an oral tablet with A9-THC (Namisol)

16:15-16:30 Franjo Grotenhermen

Practical aspects of a treatment with dronabinol (THC)

16:30-17:00 BUSINESS MEETING

European Workshop on Cannabinoid Research

17:00-18:00 Session VII - Hot topics from the lab and the clinic

Chair: R. Pertwee

17:00-17:15 Stefan Engeli

Circulating endocannabinoids are related to blood pressure in patients with obstructive sleep apnea

17:15-17:30 Attila Olah

Weed against ZIT? Cannabidiol inhibits lipid synthesis of human sebocytes both in vitro and in vivo

17:30-17:45 Linda Klumpers

Demonstrating peripheral restriction ofCB1 antagonist TM 38837 in humans

17:45-18:00 Viktor Rempel

Xanthine derivatives as novel ligands for cannabinoid receptors and the related orphan receptor GPR55

18:00-18:30 Special Presentation

Raphael Mechoulam

Beyond Cannabis and Anandamide
Chair: A. Zimmer

19:30-22:00 CONFERENCE DINNER


POSTER LIST

1 AGE-RELATED CHANGES IN THE ENDOCANNABINOID LEVELS, OXIDATIVE
STRESS AND LYSOSOMAL ACTIVITY IN MICE LACKING CB1 RECEPTOR

A. Piyanova , O. Albayram, K. Michel, R. Buchalla, C. Schwitter, B. Lutz, A. Zimmer, A. Bilkei- Gorzo

2 ROLE OF CANNABINOID 1 RECEPTORS ON HIPPOCAMPAL GABAERGIC NEURONS IN BRAIN AGING

O. Albayram , J. Alferink, A. Piyanova, K. Monory, B.Lutz, A. Zimmer, A. Bilkei-Gorzo

3 MULTITARGET DRUGS AT CB2 RECEPTOR AND BuChE FOR ALZHEIMER
DISEASE

Gonzalez-Naranjo P. , Perez C, Campillo Nuria E., Giron R., Sanchez E., Martin Ml, Gomez- Canas M., Fernandez-Ruiz J., Romero J., and J.A. Paez

4 THE COMBINATION OF D9-THC AND CANNABIDIOL REDUCES THE COGNITIVE IMPAIRMENT IN AN ANIMAL MODEL OF ALZHEIMER'S DISEASE

E. Aso , S. Juves, R. Maldonado, I. Ferrer

5 CANNABINOID RECEPTOR 1 (CB1) KNOCK-OUT AFFECTS BIOCHEMICAL
PROCESSING OF THE AMYLOID PRECURSOR PROTEIN (APP) AND LEADS TO A
DECREASE IN COGNITIVE ABILITIES IN A MOUSE MODEL OF ALZHEIMER'S
DISEASE (AD)

C. Hiebel , C. Stumm, R. Hanstein, H. Nagel, M. Purrio, A. Conrad, B. Lutz, C. Behl and A. B. Clement

6 ANXIOLYTIC-LIKE PROPERTIES OF ST4070, A NOVEL, POTENT AND SELECTIVE REVERSIBLE INHIBITOR OF FAAH

M. Maccarrone, E. M. Marco, C. Rapino, A. Caprioli, F. Borsini, G. Laviola and S. Oddi

7 A STRUCTURE-AFFINITY STUDY ON NEW RESORCINOL "HYBRIDS": ROLE OF
THE AMIDE HEAD ON THE CANNABINOID RECEPTOR INTERACTION

A. Brizzi , M. G. Cascio, F. Aiello, A. Ligresti, V. Brizzi, R. G. Pertwee, F. Corelli and V. Di Marzo

8 EFFECTS OF CANNABIDIOL AND OTHER PHYTOCANNABINOIDS ON
SEROTONIN 5-HT 1A RECEPTORS

M. G. Cascio , D. Bolognini, L. A. Stevenson and R. G. Pertwee

9 TONIC INHIBITORY EFFECT OF ENDOCANNABINOIDS ON HUMAN CONNECTIVE TISSUE- AND MUCOSAL- TYPE MAST CELL FUNCTIONS IN SITU VIA CANNABINOID RECEPTOR 1 (CB1) SIGNALING

K. Sugawara , T. Biro, A. Kromminga, D. Tsuruta, B. I Toth, N. Zakany, T. Hundt, V. Emelianov,

B. F. Gibbs, and R. Paus

10 CANNABINOID RECEPTOR TRAFFICKING IN PERIPHERAL IMMUNE CELLS IS TYROSINE PHOSPHATASE-DEPENDENT

J. Kleyer , S. Nicolussi and J. Gertsch

11 FREQUENCY-DEPENDENT MODULATION OF NORADRENERGIC TRANSMISSION BY CANNABINOIDS IN THE RAT PREFRONTAL CORTEX (PFC)

H. Richter , F. M. Teixeira, S. G. Ferreira, F. Goloncser, A. Kittel, A. Kofalvi, B. Sperlagh

12 INTERACTION OF 2-ARACHIDONOYLGLYCEROL WITH THE GABA A RECEPTOR COMPLEX

C. M. van Rijn and E. Willems-van Bree

13 DEFRAGMENTATION OF THE PERIODS OF IMMOBILITY DURING CHRONIC
ADMINISTRATION OF PHYTOCANNABINOIDS IN RATS

C. M. van Rijn , A. Hafkemeijer, M. LA Jongsma and R. J. Glas

14 PROPOFOL AT THERAPEUTIC DOSE IS NOT A HUMAN FATTY ACID AMIDE
HYDROLASE INHIBITOR

C. Jarzimski, M. Karst, A. A. Zoerner, C. Rakers, M. May, M. Suchy, D. Tsikas, J. K. Krauss, D. Scheinichen, J. Jordan, S. Engeli

15 ANTI-INFLAMMATORY EFFECT OF 5-AMINOSALICYLIC ACID ON THE PPARA SIGNALING SYSTEM IN THE HUMAN ULCERATIVE COLITIS

J. Suarez , Y. S. Romero-Zerbo, L. Marquez, F. J. Bermudez-Silva, M. Iglesias, M. Andreu, F. Rodrfguez de Fonseca

16 LIQUID EXTRACTION OF ENDOCANNABINOIDS WITH TOLUENE REDUCES
MATRIX EFFECTS AND TRANS-ACYLATION OF 2-ARACHIDONOYL GLYCEROL
TO 1-ARACHIDONOYL GLYCEROL

A. A. Zoerner , S. Batkai, S. Engeli, M. T. Suchy, J. Jordan, D. Tsikas

17 SYSTEMATIC CHARACTERIZATION OF ENDOCANNABINOID MICRODIALYSIS
 

A. A Zoerner , C. Rakers, S. Engeli, S. Batkai, M. May, J. Jordan, D. Tsikas

18 DESIGN AND SYNTHESIS OF NEW QUINOLONE-7-SUBSTITUTED-3-
CARBOXAMIDES AS POTENTIAL CB1 SELECTIVE LIGANDS

M. De Rosa , S. Pasquini, C. Mugnaini, A. Brizzi, F. Corelli, A. Ligresti and V. Di Marzo

19 IMMUNOAFFINITY CHARACTERIZATION OF PEPTIDE ENDOCANNABINOIDS
IDENTIFICATION OF N-TERMINAL EXTENDED PRECURSORS

M. Bauer and J. Gertsch

20a SYNTHESIS OF 1,3,7-TRISUBSTITUTED XANTHINE DERIVATIVES AS LIGANDS
FOR CANNABINOID AND RELATED GPCRS

D. Horn , C. E. Muller

20b XANTHINE DERIVATIVES AS NOVEL LIGANDS FOR CANNABINOID RECEPORS
AND THE RELATED ORPHAN RECEPTOR GPR55
V. Rempel , D. Horn, C. E. Muller

21 DEVELOPMENT OF POTENT ENDOCANNABINOID REUPTAKE INHIBITORS FROM
A PLANT DERIVED A/-ISOBUTYLAMIDE SCAFFOLD

S. Nicolussi, A. Chicca, M. Soeberdt, J. Gertsch

22 THE C385A MISSENSE VARIANT MODULATES ACUTE STRESS RESPONSE IN
HEALTHY HUMANS

A. Dlugos , E. Childs, A. A. Palmer and H. de Wit

23 A MOUSE LINE FOR CELL TYPE-SPECIFIC RESCUE FROM CB1 RECEPTOR
DEFICIENCY

S. Ruhle , G. Marsicano, B. Lutz

24 GENERATION OF CB2 RECEPTOR HUMANIZED MICE

B. Gennequin , D.-M. Otte, X. Miro, M. Karsak, A. M. Zimmer, A. Zimmer

25 GENERATION OF CONDITIONAL KNOCK OUT MICE FOR DIACYLGLYCEROL
LIPASE a AND (3

S. Ternes, D.-M. Otte, A.M. Zimmer, J. Schmidt, C. Hamsch, A. Zimmer

26 EVIDENCE SUPPORTING THE EXISTENCE OF AN ENDOCANNABOID
MEMBRANE TRANSPORTER INVOLVED IN CELLULAR AEA AND 2-AG UPTAKE

A. Chicca , J. Marazzi, S. Nicolussi and J. Gertsch

27 AMINO ACIDS D2.63 AND K373 ARE IMPORTANT FOR MAINTAINING THE CB1R
BINDING POCKET, WHILE RESIDUES K3.28 AND S1.39 ARE INVOLVED IN
SELECTIVE LIGAND RECOGNITION

J. P. Marcu , A. Kapur, M. Trznadel, P. H. Reggio, M. E. Abood

28 DEFINITION OF THE CELLULAR SOURCE OF ELEVATED 2-AG LEVELS IN THE
LIVER AND ANALYSIS OF 2-AG INDUCED CELL DEATH IN HEPATIC STELLATE
CELLS

A. Wojtalla , M. V. Singer, T. Sauerbruch, A. Zimmer, S. V. Siegmund

29 REGULATION OF TYPE 1 CANNABINOID RECEPTORS AND MU OPIOID
RECEPTORS BY MICRORNA AND POSSIBLE CONSEQUENCES ON DRUG
TOLERANCE

C. Borner , J. Kraus, E. Martella, V. Hollt

30 ACUTE AND CHRONIC CANNABINOID TREATMENT DIFFERENTLY AFFECT
ALCOHOL INTAKE IN PUBERTAL AND ADULT RATS

C. M. Friemel , R. Spanagel, M. Schneider

31 INVOLVEMENT OF THE ECB SYSTEM IN HEDONIC REWARD PROCESSING -
MEASURED BY THE PLEASURE ATTENUATED STARTLE PARADIGM

M. Schneider , A. Zimmer, C. Friemel, T. Brand

32 CANNABIDIOL ATTENUATES SOCIAL ISOLATION-INDUCED AGGRESSION IN
MICE

F. V. Gomes , S. F. Lisboa and F. S. Guimaraes

33 DIAGNOSIS OF MAJOR DEPRESSION USING ETHANOLAMINE PHOSPHATE
(EAP): POSSIBLE APPLICATION FOR DEVELOPMENT OF ANTIDEPRESSANT
MANIPULATING THE ENDOCANNABINOID SYSTEM

Y. Ohashi, K. Shinoda, H. Sato, K. Sasaki, H. Yamamoto, T. Ishikawa, N. Kawamura

34 DEMONSTRATING PERIPHERAL RESTRICTION OF NOVEL CANNABINOID CB1
ANTAGONIST TM38837 BY EVALUATING FOR EXPRESSION OF CONDITIONED
FEAR IN MICE

V. Micale , P. K. Norregaard and C. T. Wotjak

35 EFFECTS ON FEAR AND ANXIETY OF AAV VECTOR-MEDIATED
OVEREXPRESSION OF MAGL IN GLUTAMATERGIC NEURONS OF THE
BASOLATERAL AMYGDALA

F. Remmers , S. Guggenhuber, S. Ruehle, B. Lutz

36 AAV-MEDIATED OVEREXPRESSION OF THE CB1 RECEPTOR IN THE MPFC OF
ADULT RATS ALTERS COGNITIVE AND EMOTIONAL BEHAVIOR

A. Goepfrich , M. Klugmann, C. M. Friemel, M. Schneider

37 ACUTE AND CHRONIC EFFECTS OF CANNABINOIDS ON THE BEHAVIOUR OF
ZEBRAFISH EMBRYOS

T. Akhtar , S. Ali, H. Rashidi, F. van der Kooy, R. Verpoorte and M. K. Richardson

38 THE IMPACT OF THE ENDOCANNABINOID SYSTEM ON SOUND LOCALISATION
B. Trattner , S. Berner, B. Grothe and L. Kunz

39 CANNABINOID POTENTIATION OF GLYCINE RECEPTORS CONTRIBUTES TO
CANNABIS-INDUCED ANALGESIA

L. Zhang and W. Xiong

40 THE ROLE OF CB2 RECEPTORS IN MODULATION OF INFLAMMATORY PAIN
I. Racz , A. Markert, J. Gertsch, A. Zimmer

41 TARGETING NEUROPATHIC PAIN THROUGH ENDOCANNABINOID RECEPTOR
SIGNALING

A.-L. Klauke , I. Racz, A. Markert, J. Gertsch, A. Zimmer

42 CB2 RECEPTOR MEDIATES PHAGOCYTOSIS AND SCAR FORMATION AFTER
MYOCARDIAL INFARCTION IN MURINE HEART

G. P. Duerr , T. Heuft, G. Suchan, T. Klaas, A. Welz, A. Zimmer, B. K. Fleischmann, O. Dewald

43 EFFECTS OF HIGH GLUCOSE AND INSULIN ON VASORELAXATION TO
ANANDAMIDE

W.-S. Vanessa Ho

44 THE ENDOCANNABINOID ANANDAMIDE MEDIATES HYPOXIC PULMONARY
VASOCONSTRICTION VIA FATTY ACID AMIDE HYDROLASE (FAAH)
METABOLIZATION PRODUCTS

D. Wenzel , M. Matthey, R. Buchalla, C. Schwitter, B. Lutz, A. Zimmer, B. K. Fleischmann

45 STRATEGIC LOCALIZATION OF TRPV1 EXPRESSING CELLS IN THE BRAIN
VASCULAR SYSTEM

M. Tauchi and R. Kollmar

46 SINGLE DOSE ADMINISTRATION OF CANNABIDIOL AFTER BRAIN HYPOXIA-
ISCHEMIA AFFORDS LONG-LASTING NEUROPROTECTION IN NEWBORN RATS
 

Pazos MR, Cinquina V, Gomez A, Layunta R, Mohamed N, Martinez-Orgado J.

47 ENDOCANNABINOID CONTENT IN FETAL BOVINE SERA - UNEXPECTED
EFFECTS ON MONONUCLEAR CELLS AND OSTEOCLASTOGENESIS

J. Marazzi , J. Kleyer, J. M. Viveros Paredes, J. Gertsch

48 OSTEOCLASTOGENESIS INHIBITION BY A NOVEL CLASS OF BIPHENYL-TYPE CANNABINOID CB2 RECEPTOR INVERSE AGONISTS

J. M. Viveros Paredes, W. Schuehly, J. Kleyer, A. Huefner, S. Anavi-Goffer, S. Raduner, K.-H. Altmann and J. Gertsch

49 DO CB1 CANNABINOID RECEPTORS REGULATE INSULIN SIGNALLING IN RAT PRIMARY SKELETAL MUSCLE CELLS?

M. Haddad , K. Tsintzas, S.P.H. Alexander and A.J. Bennett

50 CB1 CANNABINOID RECEPTOR ANTAGONISM INHIBITS BALLOON-INDUCED NEOINTIMA FORMATION IN ATHEROSCLEROTIC MICE

F. Molica , F. Burger, C. M. Matter, A. Thomas, C. Staub, A. Zimmer, B. Cravatt, P. Pacher, S. Steffens


51 THE ENDOCANNABINOID SYSTEM SHOWS DIFFERENT ALTERATIONS IN IN
VITRO AND IN VIVO MODELS OF HUNTINGTON'S DISEASE

M. Maccarrone, M. Bari, N. Battista, M. Valenza, M. Malaponti, G. Catanzaro, C. Di Pancrazio, N. Mastrangelo, D. Centonze, A. Finazzi-Agro, E. Cattaneo and S. Oddi

52 DISEASE-MODIFYING EFFECTS OF WIN55.212-2 IN A MODEL OF MULTIPLE
SCLEROSIS IN MICE: ROLE OF CB1 AND CB2 RECEPTORS

E. de Lago , M. Moreno-Martet, C. Rodrfguez-Cueto, C. Palomo-Garo, C. Garcia, M. Gomez-Ruiz, J. A. Ramos and J. Fernandez-Ruiz

53 EFFECTS OF CANNABIS USE ON SOME IMMUNE PARAMETERS IN PATIENTS
WITH MULTIPLE SCLEROSIS

M. Sexton and N. Stella

54 CANNABIDIOL, NON-PSYCHOACTIVE CANNABINOID, AMELIORATES CLINICAL SYMPTOMS AND DECREASES MICROGLIAL ACTIVATION IN MOG-TREATED MICE

E. Kozela , N. Lev, A. Juknat, M. Pietr, N. Rimmerman, R. Levy, Z. Vogel

55 A NOVEL 3D MODEL OF THE HUMAN CANNABINOID RECEPTOR 2 IN ITS ACTIVE STATE HELPS TO DEVELOP NEW RADIOTRACERS FOR POSITRON EMISSION TOMOGRAPHY (PET)

R. Gunther , W. Deuther-Conrad, S. Fischer, T. Ruhl, J. Steinbach, P. Brust

56 18 FLUORINE-LABELED NITROGEN HETEROCYCLIC DERIVATIVES AS NEW
CANDIDATE FOR CANNABINOID CB2 RECEPTOR PET IMAGING

F. Castelli , G. Saccomanni, S. Bertini, S. Del Carlo, V. Di Marzo, V. Lucchesi, C. Manera, G.
Pascali, P. Salvadori, M. Macchia

57 DEVELOPMENT OF AN ULTRA SENSITIVE LC-MS/MS METHOD FOR THE
SIMULTANEOUS DETERMINATION OF A9-TETRAHYDROCANNABINOL AND ONE OF ITS MAJOR METABOLITES A9-(11-OH) TETRAHYDROCANNABINOL IN HUMAN PLASMA

M. Boterman , T. Beumer, F. Oostebring, A. Meijer and E. Oosting

58 DEVELOPMENT, VALIDATION AND USE OF A LC-MS/MS METHOD TO ASSAY
FAAH ACTIVITY IN BIOLOGICAL SAMPLES

C. Rakers , A. A. Zoerner, S. Batkai, S. Engeli, J. Jordan, D. Tsikas

59 A NEW TLC DENSITOMETRY METHOD IN A KIT-FORMAT FOR COMPLETE
SEPARATION AND VISUALISATION OF ALL CANNABINOIDS IN CANNABIS
SPECIES

R.J. Glas

60 INTESTINAL N-ACYLETHANOLAMINE LEVELS ARE DOWN-REGULATED IN BOTH MICE AND RATS BY SENSING OF DIETARY FAT

T. A. Diep , A. N. Madsen, N. Wellner, B. Hoist and H. S. Hansen

61 CIRCADIAN RHYTHM OF BLOOD ENDOCANNABINOIDS - IS FOOD INTAKE THE KEY TRIGGER?

M. May , S. Batkai, A. A. Zoerner, D. Tsikas, J. Jordan, S. Engeli

62 STUDIES ON THE ANORECTIC EFFECT OF N-ACYLPHOSPHATIDYLETHANO-
LAMINE AND PHOSPHATIDYLETHANOLAMINE IN MICE

N. Wellner , K. Tsuboi, A. N. Madsen, B. Hoist, T. A. Diep, M. Nakao, A. Tokumura, M. P. Burns, D. G. Deutsch, N. Ueda and H. S. Hansen

63 EFFECTS OF CHRONIC ADMINISTRATION OF CANNABINOID RECEPTOR
INVERSE AGONIST (AM 251) ON THE FOOD INTAKE, BODY WEIGHT GAIN AND
OXYGEN CONSUMPTION IN OBESE ZUCKER RATS

I. Merroun , J. M. Porres, G. Urbano, P. Aranda, J. Llopis, M. Errami and M. Lopez-Jurado

64 METABOLIC FINGERPRINTING OF CANNABIS SATIVA L, CANNABINOIDS AND TERPENOIDS FOR CHEMOTAXONOMIC AND DRUG STANDARDIZATION
PURPOSES

J. T. Fischedick , A. Hazekamp, T. Erkelens, Y. H. Choi, R. Verpoorte

65 CANNABINOID RECEPTOR 1 IN HODGKIN LYMPHOMA AND B-CELL NON-HODGKIN LYMPHOMA ENTITIES: EXPRESSION AND FUNCTIONAL RELEVANCE FOR SURVIVAL OF TUMOR CELLS

A. H. Benz , C. Renne, M. Koch, E. Maronde, S. Kallendrusch, B. Rengstl, S. Newrzela, S.
Hartmann, M.-L. Hansmann and F. Dehghani

66 DEVELOPMENT OF CB2 SELECTIVE CANNABINOID RECEPTOR LIGANDS AS
POTENTIAL ANTITUMOR AGENTS

V. Lucchesi , F. Castelli, C. Manera, S. Bertini, S. Del Carlo, A. Ligresti, A. M. Malfitano, G. Saccomanni, V. Di Marzo, M. Bifulco, M. Macchia

67 BASALIOMA TREATMENT WITH INTRATUMORAL INJECTIONS OF A CANNABIS-OIL EXTRACT: A SINGLE-CASE STUDY

J. Pedraza-Valiente

68 IMPROVEMENT OF CLONAL PROPAGATION OF CANNABIS SATIVA L. FOR
PHARMACEUTICAL PRODUCTION

S. Beguerie , S. Casano, G. Grassi

69 CLONING OF PHARMACEUTICAL CANNABIS THROUGH AN AEROPONIC
PROPAGATION SYSTEM

S. Beguerie , S. Casano, G. Grassi

70 ESTIMATION OF USABLE BIOMASS YIELD OF OUTDOOR CULTIVATED CANNABIS SATIVA L. PLANTS

Z. Mehmedic , S. Chandra, H. Lata, I. A. Khan and M. A. ElSohly

71 A QUESTIONNAIRE SURVEY OF PATIENTS PRESCRIBED SATIVEX AS
UNLICENSED MEDICINE

Notcutt, W.

72 GLYCINE RECEPTORS, A NEW TARGET FOR MEDICAL MARIJUANA
 

L. Zhang and W. Xiong

73 USE OF MEDICINAL CANNABIS IN THE NETHERLANDS
 

L. Wiinkoop , A. Hazekamp, R. Heerdink

74 MEDICAL CANNABIS USE IN POST-TRAUMATIC STRESS DISORDER: A
NATURALISTIC OBSERVATIONAL STUDY

75 PSYCHOSOCIAL STRESS MODULATES CIRCULATING ANANDAMIDE AND
OTHER N-ACYLETHANOLAMINES IN HEALTHY HUMANS

A. Dluqos , E. Childs, K. Stuhr, C. Hillard, H. de Wit

76 THE EFFECT OF CANNABIS INTOXICATION ON EGO EQUILIBRIUM:
INVESTIGATING THE ACUTE DEVELOPMENTAL IMPACT OF AN ALTERED STATE OF CONSCIOUSNESS

M. Metzqer

77 THE SOCIAL AND BIOETHICAL ASPECTS OF USE OF MEDICINAL CANNABIS IN CROATIA

M. Gold , S. Kantar, K. Svrznjak

78 EVALUATION OF A NEW PLATFORM TO ADMINISTER CANNABINOIDS BY
INHALING: MINIVAP® PORTABLE VAPORIZER

J. Fernandez , A. Hazehamp

79 INTOXICATIONS FOLLOWING RECREATIONAL USE OF HERBAL PRODUCTS
CONTAINING SYNTHETIC CANNABINOIDS

Bela Szabo , Volker Auwarter, Stefan Kneisel and Maren Hermanns-Clausen 





Abstract book online: